UCB Pharma Advances Next-Generation Antibody Discovery with Genedata Biologics
Leader in protein therapeutics development extends use of Genedata Biologics for next-generation antibody-based therapeutics R&D
September 17, 2012
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced a major extension of its research informatics collaboration with UCB, a leading global biopharmaceutical company. UCB has expanded its use of Genedata Biologics™ to support novel discovery technologies including all antibody and other next-generation protein therapeutics. Genedata Biologics, a first-in-class biologics data analysis and management system, already supports UCB’s global biopharma discovery and lead-finding activities in the fields of central nervous system disorders and autoimmune and inflammatory disorders.
“We are very pleased with Genedata Biologics as our central biologics registration and data management platform for biologic molecules generated at UCB,” explained Dr. Phil Scordis, Director of Informatics at UCB. “Genedata Biologics’ flexible workflow engine has helped to quickly enable us to expand the platform’s use to our new proprietary biologics discovery workflows and technologies.”
Initially, UCB implemented Genedata Biologics as the basis of their corporate-wide biological registration system for protein-based lead candidates and reagents. The system has been rolled out across UCB biopharma discovery units worldwide and supports different biologics discovery processes. Genedata Biologics is also used by a range of protein sciences groups involved in the production of proteins as research reagents for screening assay development or structural studies. The system is used to support the entire process from cloning and cell line development activities, to expression and purification, and analytics and QC reporting. The extended collaboration includes services to integrate Genedata Biologics with UCB’s data capture, ELN, logistics, and inventory management infrastructure.
“We are proud that UCB, a leading biopharmaceutical company, has selected Genedata Biologics as their global biologics registration platform and is now also using the software to support their novel biologics R&D workflows,” said Dr. Othmar Pfannes, CEO of Genedata. “Our collaboration with UCB is a perfect example of how Genedata can support the biopharmaceutical industry in scaling-up while making biologics R&D operations more efficient. By leveraging Genedata Biologics, an out-of-the-box software solution, and our scientific and technical domain expertise, we are able to quickly provide tailored IT solutions to support a large variety of biologics-specific R&D workflows and technologies."
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.